Search company, investor...
Regenetech company logo

Regenetech

regenetech.com

Founded Year

2002

About Regenetech

Regenetech develops and offers intellectual property licenses in the area of Adult Stem Cell Expansion and therapeutic applications of adult stem cells. Regenetech uses a technology discovered by NASA in space experiments for growing three-dimensional (3D) stem cells in a weightless environment.

Headquarters Location

2801 Post Oak Boulevard Suite 180

Houston, Texas, 77056,

United States

Missing: Regenetech's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Regenetech's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Regenetech Patents

Regenetech has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/28/2006

10/13/2009

Particle physics, Electricity, Nuclear physics, Elementary particles, Electromagnetism

Grant

Application Date

11/28/2006

Grant Date

10/13/2009

Title

Related Topics

Particle physics, Electricity, Nuclear physics, Elementary particles, Electromagnetism

Status

Grant

Latest Regenetech News

Global Stem Cell Partnering Terms and Agreements 2021 Report - Featuring Regenetech, Stempeutics and Arthrex Among Others - ResearchAndMarkets.com

Dec 8, 2021

Search jobs 08-Dec-2021 Global Stem Cell Partnering Terms and Agreements 2021 Report - Featuring Regenetech, Stempeutics and Arthrex Among Others - ResearchAndMarkets.com This report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in stem cell partnering Deal terms analysis Average deal terms for stem cells The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes. This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010. One of the key highlights of the report is that over 650 online deal records of actual Stem Cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. A comprehensive series of appendices is provided organized by Stem Cell partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Stem Cell partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Stem Cell technologies and products. Key benefits In-depth understanding of Stem Cell deal trends since 2010 Access to headline, upfront, milestone and royalty data Detailed access to actual Stem Cell contracts entered into by leading biopharma companies Identify most active Stem Cell dealmakers since 2010 Insight into terms included in a Stem Cell partnering agreement, with real world examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies Companies Mentioned CNA Development Arthrex Shanghai Cell Therapy Group Sinopharm 2.1. Introduction 2.3. Most active Stem Cell dealmakers 2.4. Stem Cell partnering by deal type 2.5. Stem Cell partnering by therapy area 2.6. Deal terms for Stem Cell partnering 2.6.1 Stem Cell partnering headline values 2.6.2 Stem Cell deal upfront payments 2.6.3 Stem Cell deal milestone payments 2.6.4 Stem Cell royalty rates Chapter 3 - Leading Stem Cell deals 3.1. Introduction Chapter 4 - Most active Stem Cell dealmakers 4.1. Introduction 4.3. Most active Stem Cell partnering company profiles Chapter 5 - Stem Cell contracts dealmaking directory 5.1. Introduction Chapter 6 - Stem Cell dealmaking by technology type Chapter 7 - Partnering resource center 7.1. Online partnering

Regenetech Frequently Asked Questions (FAQ)

  • When was Regenetech founded?

    Regenetech was founded in 2002.

  • Where is Regenetech's headquarters?

    Regenetech's headquarters is located at 2801 Post Oak Boulevard, Houston.

  • Who are Regenetech's competitors?

    Competitors of Regenetech include Histogen, Stemina Biomarker Discovery, Esperance Pharmaceuticals, OncoMed Pharmaceuticals, Gamida Cell and 12 more.

Compare Regenetech to Competitors

Stemina Biomarker Discovery Logo
Stemina Biomarker Discovery

Stemina Cell Discovery discovers and validates small molecules as biomarkers for high-throughput drug screening and disease diagnostics using an all human system comprised of stem cells and the company's metabolomics platform. Metabolomics aims to enable the discovery of small molecules that can be used as candidate biomarkers of disease and pharmacological efficacy or toxicity. The human embryonic stem cell metabolome is a source of candidate biomarkers to predict, diagnose or measure the progress of disease or toxic response. Stemina aims to provide compound screening and diagnostic development for the pharmaceutical and biotechnology industries and academia under contract services or joint discovery agreements.

K
Kardia Therapeutics

Kardia Therapeutics, Inc. is a research-stage biotechnology company focused on the development of cardiac regenerative therapies in the areas myocardial infarction and heart failure. Kardia Therapeutics' portfolio of technologies aims to utilize three related approaches: 1) Adult Cardiac Progenitor Cells, 2) Stem Cell Optimization Technologies, and 3) Homing/Growth Factor Therapies. Because the heart has a limited capacity for self-regeneration, Kardia's technologies have the potential to offer improved patient outcomes compared to existing treatments.

B
BresaGen

NovoCell, Inc./BresaGen is a stem cell engineering company dedicated to creating, delivering, and commercializing cell and drug therapies to treat diabetes and other chronic diseases. Novocell uses its cell encapsulation technology and expertise in cell implantation to develop a renewable source of specialized cells for the treatment of cellular diseases. Bresagen represents a division of Novocell's research operation.

E
Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

NellOne Therapeutics Logo
NellOne Therapeutics

NellOne Therapeutics is a regenerative-medicine spinout of the U.S. Department of Energy's Oak Ridge National Laboratory (ORNL). The start-up, in the proof-of-efficacy stage, is dedicated to exploring the creation of protein therapeutics for their potential in restoring tissue mass andfunction in patients recovering from heart attacks. Current therapeutic approaches, such as those based on stem cells, have shown the potential to restore tissue mass, but with only limited recovery of function. General Partner Tracy Warren is acting CEO and a member of the Board of Directors. (See deal announcement.)

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.